Compare IPGP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | ACAD |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 2000 | 2000 |
| Metric | IPGP | ACAD |
|---|---|---|
| Price | $101.67 | $21.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $131.40 | $30.55 |
| AVG Volume (30 Days) | 586.5K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | 69.12 |
| EPS | ★ 0.04 | 0.02 |
| Revenue | ★ $1,003,777,000.00 | $726,437,000.00 |
| Revenue This Year | $12.18 | $18.80 |
| Revenue Next Year | $8.44 | $11.70 |
| P/E Ratio | $2,625.50 | ★ $1,104.75 |
| Revenue Growth | 2.73 | ★ 40.45 |
| 52 Week Low | $63.33 | $19.69 |
| 52 Week High | $155.82 | $28.35 |
| Indicator | IPGP | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 44.10 |
| Support Level | $76.61 | $21.28 |
| Resistance Level | $129.39 | $22.64 |
| Average True Range (ATR) | 5.71 | 0.76 |
| MACD | -0.85 | -0.05 |
| Stochastic Oscillator | 39.04 | 1.46 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.